EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy

Yingjie Li, Fei Liang, Zhongwu Li, Xiaoyan Zhang, Aiwen Wu

Clinical Colorectal Cancer · 2025

DOI: 10.1016/j.clcc.2024.07.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Yingjie Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoadjuvant Therapy, DNA Polymerase II, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy and safety of neoadjuvant immunotherapy for patients with microsatellite instability-high (MSI-H) or DNA polymerase ε (POLE)-mutated locally advanced colorectal cancer (LACRC) with bulky tumors. PATIENTS: We retrospectively reviewed 22 consecutive patients with MSI-H or POLE-mutated LACRC with bulky tumors (>8 cm in diameter) who received preoperative programmed death-1 blockade, with or without CapOx chemotherapy. MAIN OUTCOME MEASURES: Pathological complete response (pCR), clinical complete response (cCR), toxicity, R0 resection rate, and complications were evaluated. Survival outcomes were analyzed using the Kaplan-Meier method. Multiplex immunofluorescence analysis were performed before and after treatment. RESULTS: The incidence of immune-related adverse events (irAEs) was 36.4% (8/22). Five of 22 patients presented with surgical emergencies, most commonly perforation or obstruction. The 22 patients underwent a median 4 (1-8) cycles. Two patients were evaluated as cCR and underwent a watch and wait strategy. The R0 resection rate was 100.0% (20/20) and pCR rate was 70.0% (14/20). Twelve of 14 cT4b patients (85.7%) avoided multivisceral resection, and 10 of them achieved pCR or cCR. In the two patients with POLE mutations, one each achieved pCR and cCR. No Grade III/IV postoperative complications occurred. The median follow-up was 16.0 months. Two-year event-free and overall survival for the whole cohort was both 100%. CONCLUSIONS: Preoperative immunotherapy is the optimal option for MSI-H or POLE-mutated LACRC with bulky tumors, especially cT4b. Preoperative immunotherapy in patients with T4b CRC can reduce multivisceral resection and achieve high CR rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNeoadjuvant TherapyDNA Polymerase IIAntineoplastic Combined Chemotherapy ProtocolsPoly-ADP-Ribose Binding ProteinsImmune Checkpoint InhibitorsImmunotherapyHumansMicrosatellite InstabilityMaleFemaleMiddle AgedAgedRetrospective StudiesMutationAdultOxaliplatinTumor Burden

Stichwörter der Autor:innen

LACRCMSI-HPD-1 blockadePOLE mutation

Substanzen

POLE protein, humanDNA Polymerase IIPoly-ADP-Ribose Binding ProteinsImmune Checkpoint InhibitorsOxaliplatin

Autor:innen und Institutionen

  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Gastrointestinal Cancer Center, Unit III, Peking University Cance…
  • Department of Biostatistics, Clinical Research Unit, Institute of Clinical Science Zhongshan Hospital, Fudan University, Shanghai, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Pathology, Peking University Cancer Hospital & Inst…
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Radiology, Peking University Cancer Hospital & Inst…

Zitieren

APA

Li, Y., Liang, F., Li, Z., Zhang, X., & Wu, A. (2025). Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.07.001

Vancouver

Li Y, Liang F, Li Z, Zhang X, Wu A. Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.07.001

BibTeX
@article{Li2025,
  author = {Li, Yingjie and Liang, Fei and Li, Zhongwu and Zhang, Xiaoyan and Wu, Aiwen},
  title = {Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy},
  journal = {Clinical Colorectal Cancer},
  year = {2025},
  doi = {10.1016/j.clcc.2024.07.001}
}
Kostenlos starten →